KTTAW — Pasithea Therapeutics Corp.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1841330 ·
Last close
$0.00
Market Cap
—
52W High
$0.00
52W Low
$0.00
ADV30
383
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -5,713,282 | -5,273,852 | 51,709,945 | 45,663,782 | 1,870,258 |
| Mar 2026 | 0 | — | -4,876,644 | -2,869,482 | 56,354,901 | 50,400,377 | 1,542,451 |
| Dec 2025 | 0 | — | -10,256,162 | -10,110,868 | 60,240,070 | 55,158,939 | 5,020,832 |
| Sep 2025 | 0 | — | -3,110,055 | -3,037,420 | 13,630,664 | 4,122,953 | 1,423,982 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,942,953
Investing CF
$0
Financing CF
$62,045,244
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-72,879,943
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-22,053,760
Pretax Income TTM
$-19,733,927
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,857,295 | -20,427,683 | 60,240,070 | 5,020,832 | 55,219,238 | -15,211,490 |
| Dec 2024 | 0 | -14,249,962 | -13,904,584 | 16,064,719 | 1,282,043 | 14,782,676 | -13,923,438 |
| Dec 2023 | 0 | -15,979,361 | -15,961,658 | 26,116,858 | 2,718,406 | 23,398,452 | -13,425,411 |
| Dec 2022 | 0 | -12,588,971 | -13,936,452 | 45,180,089 | 2,681,841 | 42,498,248 | -13,691,158 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
2026-07-21 11:00 · Yahoo
New Strong Buy Stocks for July 20th
2026-07-20 09:03 · Yahoo
Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference
2026-06-15 11:02 · Yahoo
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
2026-04-20 11:01 · Yahoo
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
2026-09-14 11:00 · Yahoo
Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
2026-07-08 11:02 · Yahoo
Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus
2026-06-30 11:00 · Yahoo
Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial
2026-06-16 11:00 · Yahoo
Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-06-10 13:55 · Yahoo
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
2026-06-02 11:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.